866-997-4948(US-Canada Toll Free)

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 52 Pages


Global Markets Directs, \'Genital Warts (Condylomata Acuminata) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). 

Genital Warts (Condylomata Acuminata) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Genital Warts (Condylomata Acuminata).
  • A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Genital Warts (Condylomata Acuminata) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Genital Warts (Condylomata Acuminata) 7
Genital Warts (Condylomata Acuminata) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Genital Warts (Condylomata Acuminata) Therapeutics -  Products under Development by Companies 13
Companies Involved in Genital Warts (Condylomata Acuminata) Therapeutics Development 14
Helix BioPharma Corp. 14
Inovio Biomedical Corporation 15
NanoViricides, Inc. 16
NexMed, Inc. 17
G&E Herbal Biotechnology Co., Ltd. 18
Anaconda Pharma 19
Telormedix SA 20
Genetic Immunity, LLC 21
Moberg Derma AB 22
Laboratorio Elea S.A.C.I.F. and A 23
Genital Warts (Condylomata Acuminata) -  Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
interferon alpha-2b - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TMX-202 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SR-T100 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HupaDerm Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
fluorouracil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
imiquimod - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AP-611074 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SynCon HPV Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HerpeCide-I - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Genital Warts (Condylomata Acuminata) Therapeutics -  Drug Profile Updates 39
Genital Warts (Condylomata Acuminata) Therapeutics - Dormant Products 43
Genital Warts (Condylomata Acuminata) -  Product Development Milestones 44
Featured News & Press Releases 44
Jan 26, 2012: Hemispherx Biopharma Gains Regulatory Approval In Latin America For Alferon N Injection 44
Jan 25, 2012: Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis Or Type 1 Diabetes After Vaccination 44
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck\'s GARDASIL 45
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 46
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 47
Aug 17, 2011: Hemispherx Biopharma Submits Regulatory Approval For Alferon In Argentina 47
Jul 01, 2011: Merck Receives Approval To Market GARDASIL In Japan 48
Apr 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 48
Mar 25, 2011: FDA Approves Graceway’s Zyclara Cream For Treatment Of External Genital Warts 49
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 49

Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Table


Number of Products Under Development for Genital Warts (Condylomata Acuminata), H1 2013 7
Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Helix BioPharma Corp., H1 2013 14
Inovio Biomedical Corporation, H1 2013 15
NanoViricides, Inc., H1 2013 16
NexMed, Inc., H1 2013 17
G&E Herbal Biotechnology Co., Ltd., H1 2013 18
Anaconda Pharma, H1 2013 19
Telormedix SA, H1 2013 20
Genetic Immunity, LLC, H1 2013 21
Moberg Derma AB, H1 2013 22
Assessment by Monotherapy Products, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 28
Genital Warts (Condylomata Acuminata) Therapeutics - Drug Profile Updates 39
Genital Warts (Condylomata Acuminata) Therapeutics - Dormant Products 43

List of Chart


Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2013 7
Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 24
Assessment by Route of Administration, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Molecule Type, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *